-
The Health Service Executive has determined that the spinal muscle atrophy drug Spinraza is not cost-effective at its current price, The Irish Times reported Friday.
-
The HSE determined that the treatment could carry a cost of 20 million euros over five years, while it was not able to reach an accord with the manufacturer regarding a viable price.
-
The regulator noted that Spinraza would carry a cost of 600 000 euros for the first year and 380 000 euros for each successive year.
-
The HSE stated that it was "obligated to ensure that expenditure of this scale must represent evidence of clinical and cost-effectiveness."










(All Rights Reserved)